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A B S T R A C T
Many guanide-containing drugs are antihyperglycaemic but most exhibit toxicity, to the extent that only the
biguanide metformin has enjoyed sustained clinical use. Here, we have isolated unique mitochondrial redox
control properties of metformin that are likely to account for this diﬀerence. In primary hepatocytes and H4IIE
hepatoma cells we found that antihyperglycaemic diguanides DG5-DG10 and the biguanide phenformin were up
to 1000-fold more potent than metformin on cell signalling responses, gluconeogenic promoter expression and
hepatocyte glucose production. Each drug inhibited cellular oxygen consumption similarly but there were
marked diﬀerences in other respects. All diguanides and phenformin but not metformin inhibited NADH oxi-
dation in submitochondrial particles, indicative of complex I inhibition, which also corresponded closely with
dehydrogenase activity in living cells measured by WST-1. Consistent with these ﬁndings, in isolated mi-
tochondria, DG8 but not metformin caused the NADH/NAD+ couple to become more reduced over time and
mitochondrial deterioration ensued, suggesting direct inhibition of complex I and mitochondrial toxicity of DG8.
In contrast, metformin exerted a selective oxidation of the mitochondrial NADH/NAD+ couple, without trig-
gering mitochondrial deterioration. Together, our results suggest that metformin suppresses energy transduction
by selectively inducing a state in complex I where redox and proton transfer domains are no longer eﬃciently
coupled.
1. Introduction
Recently we have been using analogues of metformin to study how
cellular eﬀects of metformin relate to its chemical properties, which
include a strongly hydrophilic character, metal-binding and a pKa
within the physiological pH range [1–6]. This collection of properties is
not shared by other guanidine-containing compounds although many
do have mitochondrial and antihyperglycaemic eﬀects. In the 1920s for
example, before the discovery of biguanides [7,8], related compounds
known as diguanides [9] were brieﬂy evaluated as antidiabetic agents.
Unlike biguanides, in diguanides, the two guanidine groups are sepa-
rated by an alkyl chain of variable length (Fig. 1). In this series, anti-
hyperglycaemic eﬀects were found to increase, in proportion with
toxicity, up to a linker size of 10–12 carbons [10,11]. To achieve the
maximum eﬀect, the most potent and toxic diguanide, (N,N'-1,10-De-
canediylbisguanidine, synthalin A, termed DG10 in our study, Fig. 1b)
was used in humans but caused liver toxicity [12]. Owing to this failure,
there has been little investigation of the mechanism of action of syn-
thalins. Although the mechanism of antihyperglycaemic eﬀects is
poorly understood for either drug class, inhibition of mitochondrial
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respiration has been observed in response to both diguanides and bi-
guanides [13,14]. Early studies suggested that mitochondrial eﬀects
might be due to the ability of guanidine compounds to alter the func-
tional and physical structure of membranes [15,16]; however, this
model does not readily account for the widely diﬀering toxicities and
potencies of diguanides compared with biguanides and in addition
metformin is one of the most hydrophilic biguanides, unlikely to in-
teract signiﬁcantly with membranes. Later studies suggested that met-
formin acts by inhibiting complex I in the electron transport chain
[14,17]. Mitochondrial suppression by metformin activates AMPK
[18–20], which has emerged as a common cellular response to bigua-
nides, thiazolidinediones and salicylates [19,21–23]; however, there
are other possible targets, some of which are AMPK-independent. These
include regulation of glucose 6-phosphate levels [24], depho-
sphorylation of the ribosomal protein S6 by metformin [25,26] and
suppression of redox transfer by mitochondrial glycerophosphate de-
hydrogenase (mGPD) [27]. For mGPD, it has been argued elsewhere
that eﬀects on glucose production might require additional inhibition of
the alternative redox malate/aspartate shuttle [28]. None of these
models readily explain the suppression of weight gain that is one of the
key clinical hallmarks of metformin treatment [29].
Recent work on complex I has found evidence for diﬀerent modes of
complex regulation by metformin compared with rotenone, which is a
neurotoxic complex I inhibitor [30]. In the current study we have in-
vestigated diﬀerences between the actions of metformin, diguanides
and other guanide containing drugs, as these diﬀerences might ulti-
mately explain the lower toxicity of metformin compared with other
electron transport chain inhibitors. Investigating the impact of these
agents on cellular oxygen consumption, gluconeogenic gene regulation,
signalling and glucose production, we found that phenformin and
Fig. 1. Comparison of biguanide and diguanide
compounds on cells. Structures of biguanides (a)
and diguanides (b) are shown. (c, d) H4IIE liver cells
had serum removed for 2 h and then were treated
with the compounds shown for 3 h, prior to lysis and
SDS-PAGE as detailed in the Methods.
Immunoblotting was performed using two ACC an-
tibodies, one that detects ACC phosphorylated on
Ser79 (pACC Ser 79) and another that detects ACC
whether or not it is phosphorylated. A third antibody
detects AMPK when it is phosphorylated on Thr 172
(pAMPK Thr 172) and a fourth detects AMPK whe-
ther or not it is phosphorylated. Finally two anti-
bodies that detect S6 protein were used. One detects
S6 phosphorylation of residues 240 and 244 (pS6
240/244), whilst a second detects S6 regardless of
phosphorylation. For each section, the phosphoryla-
tion responses shown are representative of observa-
tions from at least three similar experiments.
Quantitation of replicates by densitometry appears in
the supplementary Fig. 1.
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several diguanides induce eﬀects similar to metformin on these outputs.
Our studies have however isolated diﬀerences in mitochondrial re-
sponses to these other agents that are likely to contribute towards ob-
served diﬀerences in toxicity.
2. Methods
2.1. Materials
Diamines used in synthesising diguanides, methylisourea and the
compound AG12 were sourced from Sigma Aldrich. DG4 and DG10
came from Tocris. DG6 came from Santa Cruz Biotechnology. The an-
tibodies used have been described previously [2,23]. Brieﬂy, the anti-
body to Ser79-phosphorylated acetyl-CoA carboxylase (ACC) was a gift
from the Division of Signal Transduction Therapy at the University of
Dundee. Total ACC, total AMP activated protein kinase (AMPK) α,
Thr172-phosphorylated AMPKα, total S6 ribosomal protein and Ser
240/244-phosphorylated S6 antibodies for immunoblotting were from
Cell Signalling Technology. Actin antibody was from Merck. Antibodies
used in the AMPK activity assays were a generous gift from Prof D.
Grahame Hardie at the University of Dundee. Chemical structures were
drawn using ChemSketch.
2.2. Diguanide synthesis
Diguanides were synthesized using a method adapted from Tricot
[31] by reacting 1 mol of a diamine with 2 mol of methylisourea. The
methylisourea was dissolved in ice-cold ultrapure water and the pH
increased to 10 by drop-wise addition of 5 M KOH. The diamine was
added and this was incubated for three hours, performing 15 min
checks to ensure that the pH was maintained at 10. The guanidinylated
products are insoluble at pH 10 and precipitates formed were collected
by centrifugation and washed twice with 10 ml ice cold ultrapure water
by re-centrifugation. The ﬁnal precipitates collected were frozen at
−20 °C and freeze dried. The success of the syntheses was initially
assessed by positive mode direct injection mass spectrometry, then the
purity of the diguanides conﬁrmed by liquid chromatography mass
spectrometry with MS2 fragmentation using an ion-pairing separation
method (see Supplementary materials for details). In our experience
with this method, the purity of the product was dictated predominantly
by the purity of the starting material.
2.2.1. H4IIE cell culture and lysis for immunoblotting
Maintenance of H4IIE cells in DMEM (31885 Invitrogen) plus 5%
Fetal calf serum (Seralab) has been described previously [2,32–34].
Cells were used for no more than 30 passages. Brieﬂy, prior to an ex-
periment being carried out, fresh medium was added the evening be-
fore. Two hours prior to stimulation on the day of the experiment, cells
were placed in DMEM without serum. Cells were scraped into ice-cold
lysis buﬀer: (50 mM Tris acetate pH7.5, 1% (w/v) Triton ×100, 1 mM
EDTA, 1 mM EGTA, 0.27 M sucrose, 50 mM NaF, 1 mM sodium ortho-
vanadate, 10 mM β glycerophosphate, 5 mM sodium pyrophosphate,
1 mM benzamidine, 0.2 mM phenylmethylsulfonyl ﬂuoride (PMSF) and
0.1% (v/v) β-mercaptoethanol) and then prepared for SDS-PAGE and
immunoblotting as described previously [35,36]. Protein concentration
was measured using Bradford reagent (Pierce). Immunoblot densito-
metry was performed with Image Studio Lite version 5.2 (LI-COR).
2.2.2. Preparation of cell extracts, immunoprecipitation and assay of
AMPK
This was carried out essentially as described previously [2]. Brieﬂy,
cells were washed twice in ice-cold PBS then harvested in ice-cold lysis
buﬀer (50 mM Tris-HCl, pH 7.4, 50 mM sodium ﬂuoride, 5 mM sodium
pyrophosphate, 1 mM EDTA, 1 mM EGTA, 150 mM sodium chloride,
1 mM dithiothreitol (DTT), 0.1 mM benzamidine, 0.1 mM PMSF, 1%
Triton X-100, and 5 μg/ml soybean trypsin inhibitor). Lysates were
cleared of debris by centrifugation at 13,000g for 15 min at 4 °C, and
the protein concentration measured as in the previous section. Cell
extracts were incubated overnight with protein G sepharose conjugated
to both anti-AMPKα1 and AMPKα2 antibodies (generously gifted by
Professor Grahame Hardie) [37]. Immunoprecipitates were pelleted
and rinsed twice with 1 ml ice-cold buﬀer (as above but with 0.5 M
NaCl) and once with ice-cold HEPES buﬀer (50 mM HEPES pH 7.4,
0.03% Brij-35 and 1 mM DTT). AMPK kinase activity was assayed at
30 °C, in the presence of 0.1 μCi of [γ-32P]ATP, 0.33 mM cold ATP,
8.3 mM MgCl2, 0.33 mM AMP, and 0.33 mM HMRSAMSGLHLVKRR
(SAMS) peptide. Kinase activity is expressed as phosphate incorporation
into 1 nmol substrate in 1 min per mg of protein. Each bar of a graph
consists of data from at least six separate immunoprecipitations, each
from a separate dish of cells.
2.3. Hydrophobicity
Molecular representations of log P were generated in Marvin Sketch,
as were calculations of log P, with 1:1:1 weighting for VG [38], KLOP
[39] and PHYSPROP approaches.
2.3.1. Luciferase reporter and WST-1 assays
The reporter cell line LLHG stably expresses the human glucose 6-
phosphatase promoter upstream of the luciferase reporter gene. This
cell line was a generous gift from Dr Calum Sutherland. LLHG cells were
plated into 12 well plates and left overnight. Cells were washed once in
serum-free DMEM before serum starving for 6 h and subsequent over-
night treatment with dexamethasone and cAMP [23] and drugs as in-
dicated in the ﬁgures. For lysis, cells were washed once in PBS before
addition of 1× Cell Culture Lysis Buﬀer (Promega). Wells were scraped
and lysates spun for 2 mins, 4 °C, 13,000 rpm. For luciferase assay,
10 μl lysate was added to a 96-well, white walled, clear bottom plate
and 100 μl luciferase assay reagent (Promega) added before quantiﬁ-
cation of luminescence. To correct for well-to-well variation, protein
concentration was determined by Bradford assay. Data is represented as
RLU/mg protein. Eﬀects of each dose were measured at least six times,
each from a separate well of cells. For WST-1 assays, H4IIE cells were
seeded on a 96 well plate, placed in serum-free medium and treated
with the appropriate drugs. WST-1 mixture (Roche) was added to each
well, mixed and incubated for two hours. Eﬀects of each dose were
measured at least eight times, each from a separate well of cells. The
absorbance of each sample was measured using a spectrophotometer at
a wavelength of 440 nm.
2.3.2. Measurement of whole-cell oxygen consumption rate
Using the Seahorse XF24, OCR was measured as described pre-
viously [2]. Brieﬂy, cells were plated at a density of 1 × 106 cells per
well in serum-containing medium. Once attached, cells were washed
once in serum-free DMEM and incubated for 2 h with de-gassing for the
ﬁnal hour. For the assay, cells were incubated in unbuﬀered DMEM
containing 1 g/L glucose, 200 mM Glutamax-1, 100 mM sodium Pyr-
uvate, 30 mM NaCl. Baseline OCR was measured for 30 mins before
injection of appropriate compounds. OCR was continuously measured
for a period of 145 min before uncoupling by addition of 100 uM 2,4
dinitrophenol (2,4, DNP).
2.4. Glucose assay
Treatment of cells for hepatocyte glucose production was carried
out essentially as described previously, using primary mouse hepato-
cytes [2,5,23,40]. Glucose production was determined after a 12 h in-
cubation period in glucose-free DMEM with or without diguanide
analogues, 2 mM metformin or 100 µM cAMP (Calbiochem, 116812).
At the end of the incubation period of 12 h, medium was collected and
glucose concentration determined by the hexokinase/glucose-6-P de-
hydrogenase method. Each bar of a graph consists of data from at least
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three separate measurements, each from a separate dish of cells, as-
sayed by GAGO assay as described earlier [5].
2.4.1. Submitochondrial particles and intact mitochondria
Rat liver mitochondria were prepared in 70 mM sucrose, 210 mM
mannitol, 5 mM HEPES, 1 mM EGTA and 0.5% fatty-free bovine serum
albumin, pH 7.2 essentially as described by [41,42]. The excised liver
was cut with scissors to approx. 4-mm diameter pieces and homo-
genized in a Teﬂon-pestle Potter-Elvehjem homogenizer with two
passes at 300 rpm. The homogenate was centrifuged at 750×g and the
supernatant centrifuged at 8000×g. The pellet was resuspended in the
isolation medium and centrifuged at 8000×g and the pellet re-
suspended in a volume of 1 ml/g original liver weight and kept in an ice
bath.
Submitochondrial particles (SMP) were prepared according to [43]
by suspending rat liver mitochondria in 30 mM potassium phosphate
buﬀer, 0.4 mM EDTA and sonication for a total of 120 s with a 50%
duty cycle in a Branson Soniﬁer Cell Disruptor B-30 using power setting
4 and a micro tip. The suspension was centrifuged at 8000×g and the
resulting supernatant at 105,000×g for 45 min in a Ti60 ﬁxed-angle
rotor in a Beckman L8-70 M ultracentrifuge. The pellet was suspended
in 30 mM potassium phosphate, pH 7.4. All manipulations, including
chopping the liver, homogenizing, re-suspending and sonication were
performed on an ice/water bath, centrifugation, and ultracentrifugation
were performed in refrigerated centrifuges in rotors pre-cooled to 4 °C.
Protein concentration in mitochondria and submitochondrial particles
was measured with the biuret method.
2.4.1.1. Fluorometry. NADH (excitation 340 nm, emission 460 nm)
ﬂuorescence was measured in a Fluoromax-2 spectroﬂuorometer
(Horiba Jobin Yvon, Inc., Edison, NJ, U.S.A).
Oxygen consumption by mitochondrial suspensions was measured
with a polarographic Rank Brothers oxygen electrode with Perspex
chamber (Rank Brothers, Cambridge, U.K.) with a magnetic stirrer. In
experiments where ﬂuorescence and oxygen consumption were mon-
itored simultaneously, the ﬂuorometric 1 cm × 1 cm cuvette was
equipped with a magnetic stirrer, a stopper with an injection port and a
miniature oxygen electrode (MI-730, Microelectrodes, Inc., Bedford,
NH, U.S.A.).
2.4.2. Complex I electron transfer to hydrophilic electron acceptors
This was measured using the MitoTox Complex I OXPHOS Activity
Microplate Assay (AbCam, ab109903). The assay was performed es-
sentially following the manufacturer's instructions. The only diﬀerence
was that ubiquinone was substituted with either 200 µM paraquat
(Sigma, 36541) or 1 mM K3Fe(CN)6 (Sigma, 702587). Diﬀering doses of
metformin and DG5 as indicated were used as the compounds to be
tested.
2.5. Data and statistical analyses
Errors in bar graphs are expressed as mean± SEM. Comparisons
between groups were made by one-way or two-way ANOVA with post-
hoc test using Prism. EC50s and IC50s were determined using Prism.
Diﬀerences were considered statistically signiﬁcant if P was less than
0.05. *** denotes p<0.001; ** denotes p< 0.01 and * denotes
p<0.05.
3. Results
3.1. Diguanides induce metformin-like eﬀects on AMPK signalling and S6
phosphorylation
In the ﬁrst experiments we compared the eﬀect of commercially
available diguanides with metformin (Fig. 1a,b) on AMPK and S6 sig-
nalling, focusing on metabolic signalling responses that we have studied
previously in liver cells [2,5]. At a single concentration, we found that
two diguanides, 1,10-Bis(guanidino)decane (synthalin A, termed DG10
in this study) and 1,6-Bis(guanidino)hexane (DG6 in this study) had
eﬀects on both AMPK and S6 phosphorylation at 25 μM, whereas 1,4-
Bis(guanidino)butane (arcaine, DG4 in this study) was ineﬀective
(Fig. 1c, quantiﬁed in supplementary Fig. 1). Previous studies also es-
tablished that alkylguanidines with chain lengths comparable with
synthalin act as even more potent mitochondrial inhibitors than di-
guanides or biguanides [13] and therefore we tested dodecylguanidine
(AG12), the most potent of these, and found that it too activated AMPK
and suppressed S6 phosphorylation (Fig. 1c), demonstrating that the
second guanidine group is dispensable for eﬀects of diguanides on these
signalling pathways.
In dose response experiments, we found that DG4 induced no apparent
changes in AMPK, ACC or S6 at 2 mM, whilst the eﬀects of DG10 on these
readouts were apparent in the low micromolar range (Fig. 1d, calculated
EC50s on ACC and AMPK and IC50s on S6 phosphorylation in Table 1a).
Previous studies on glycaemia carried out in the 1930s [44] also found
that diguanides with more than four carbons act very much more potently
than biguanides. To study this further, we synthesized diguanides that are
not commercially available, DG5, DG7 and DG8, using a modiﬁcation of
an earlier synthesis protocol. In this reaction, the products precipitate but
the reactants remain in solution, which enabled us to obtain very pure
preparations. Indeed, LC-MS analysis yielded single peaks of the expected
mass for all diguanide compounds with estimated purity>95% (Fig. 2a).
MS and MS2 data are presented (Supplementary Fig. 2). One eﬀect of in-
creasing chain length is increased hydrophobicity, and to enable a further
test of the importance of this property in the action of the diguanides, an
additional analogue was synthesized where the alkane chain in DG8 was
disrupted by replacement with an amine group, to generate DG8N
(Fig. 2b). Calculated hydrophobicity maps are presented showing the ef-
fects of this substitution compared with DG8 (Supplementary Fig. 3a,b).
DG8N has a lower hydrophobicity than DG4 (clogD −10.08 against
−7.68).
Table 1
Densitometric determination of EC50s (μM) and 95% CI of diguanides on ACC and AMPK phosphorylation and IC50s on S6 phosphorylation.
A DG4 DG5 DG6 DG7 DG8 DG10 DG8N
pACC >500 n = 3 11.0 (5.2–23.3) n = 3 2.4 (1.3–4.6) n = 4 3.4 (1.8–6.2) n = 5 3.1 (1.3–7.6) n = 3 2.2 (1.0–4.9) n = 4 >500 n = 3
pAMPK >500 n = 2 12.9 (4.7–35.1) n = 3 1.4 (0.6–3.0) n = 3 3.7 (1.6–8.4) n = 4 2.5 (1.5–4.2) n = 3 1.2 (0.8–1.8) n = 4 >500 n = 3
pS6 >500 n = 3 536 (163–1750) n = 3 2.8 (1.8–4.1) n = 3 4.9 (2.3–10.3) n = 5 14.8 (11–19) n = 3 3.9 (2.0–7.3) n = 4 >500 n = 3
B 2-methyl DG6 1-ethyl 2,2-dimethyl
DG5 DG5
pACC 16 (7.4–33) n = 3 >200 n = 3 >200 n = 3
pAMPK 27 (18–40) n = 3 >200 n = 3 >200 n = 3
pS6 32 (24–43) n = 3 >200 n = 3 >200 n = 3
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3.2. A hydrophobicity threshold aﬀecting potency of diguanides on AMPK,
gluconeogenic gene expression and hepatocyte glucose output
We examined eﬀects of synthesized diguanides on cell signalling
(Fig. 2c) and calculated EC50s for ACC/AMPK phosphorylation and
IC50s for S6 phosphorylation by analysis of densitometry data from
blots. We found that DG5 was less potent than DG7, DG8 and DG10 on
ACC, AMPK and S6 phosphorylation, with EC50s and IC50s for these
latter drugs in the low micromolar range (Table 1a). The lack of eﬀect
of DG4 suggests that a chain length threshold of ﬁve is required for
eﬀects at this time-point. When we assayed eﬀects of the drugs on cell
AMPK activity, we found that DG5, the least potent of the active
compounds, and DG10, the most potent, both increased AMPK activity
at least as well as metformin and at much lower concentrations
(Fig. 2d). To investigate further whether either chain length or hydro-
phobicity correlated with the potency of diguanide analogues, we
compared DG8 with DG8N. In parallel experiments, we demonstrated
low micromolar eﬃcacy of DG8 on signalling responses (Fig. 2e) whilst
in contrast, DG8N was inactive at much higher concentrations (Fig. 2e).
The western blotting data outlined above suggests that diguanides
DG4-6 are progressively more potent as hydrophobicity increases,
plateauing from DG6 upwards (Figs. 1d and 2c, e). We recognize that
western blotting is best described as a semi-quantitative technique and
to carry out further comparison of the diguanides and biguanides, we
Fig. 2. Synthesis and analysis of additional DG compounds and eﬀects on cells.(a) LCMS of synthesized diguanide compounds. (b) DG8N structure. Hydrophobicity maps are
presented in supplementary Fig. 3. (c,e) H4IIE liver cells had serum removed for 2 h and then were treated without (‘0’) or with the compounds shown for 3 h, prior to lysis and SDS-PAGE
as detailed in the Methods. The dose responses shown are representative of observations from at least three similar experiments, as detailed in Table 1a. Densitometric determination of
IC50s and EC50s of replicates is also given in Table 1a. AMPK activity in response to 2 mM metformin, 100 μM DG5 and 10 μM DG10 treatment is detailed in (d) Assay of AMPK
immunoprecipitated from drug-treated cells. A one-way ANOVA was carried out to determine diﬀerences between treated and untreated columns. The p value comparing DG5 and DG10
is also shown. Each bar of the graph is composed of data derived from at least eight separate immunoprecipitations.
Table 2
IC50s (μM, except values in italics, mM) and 95% CI of drugs on G6Pase luciferase promoter activity and IC50s determined by WST-1 assay.
DG4 DG5 DG6 DG7 DG8 DG10 Biguanide Metformin Phenformin
G6Pase 597 (435–820) 20.0 (12.6–31.8) 1.8 (1.6–2.0) 1.8 (1.5–2.1) 0.8 (0.7–0.9) 1.1 (0.9–1.5) 1.9 mM (1.6–2.3) 1.2 mM (0.8–1.8) 8.2 (4.8–13.9)
WST-1 173.5 (124.2–242.3) 39.0 (10.9–138.9) 4.5 (3.2–6.4) 4.0 (2.8–5.5) 1.6 (1.2–2.0) 3.4 (2.3–5.1) > 500 >500 57.8 (26.1–127.6)
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measured metformin-like eﬀects of the compounds on activity of the
glucose 6-phosphatase promoter (Table 2). Plotted on a graph, potency
of the diguanides and biguanides both increased with the calculated
LogD, with a sharp potency step-up, greatly lowering IC50s between
DG4 and DG6 in diguanides and between biguanide/ metformin and
phenformin in the biguanide drugs (Fig. 3a, squares L-R are DG4, DG5,
DG6, DG7, DG8, DG10, whilst triangles L-R are biguanide, metformin,
phenformin). The diﬀerence in hydrophobicity between metformin and
phenformin due to the presence of the phenyl ring in phenformin is
presented in Supplementary Fig. 4a,b. The IC50 of phenformin is well
within the range exhibited by DGs, whilst the other two biguanides are
less potent (Fig. 3a). A comparison of DG8 and DG8N showed a striking
diﬀerence between the potencies of these two analogues, as DG8
inhibited the gene promoter at concentrations as low as 1 μM, while in
contrast DG8N was ineﬀective at millimolar levels (Fig. 3b).
We also investigated the eﬀects of DG5, DG8 and DG8N on hepa-
tocyte glucose production, as this is thought to be the major clinical
hallmark of metformin action [45,46]. We found that the eﬀects of the
drugs were similar to those that we had observed on AMPK phos-
phorylation, as DG5 and DG8 both suppressed hepatocyte glucose
production, in a dose-dependent manner whilst DG8N was ineﬀective
(Fig. 3c). In primary hepatocytes we found a similar pattern of signal-
ling, with DG5 and DG8 active but DG8N inactive on AMPK and ACC
phosphorylation (Fig. 3d). In addition, consistent with recent work of
ours that mitochondrial inhibition by biguanides can inhibit NF-κB
signalling [5], we found that DG5 and DG8 but not DG8N inhibited
Fig. 3. Relationship between EC50 on G6Pase
promoter activity, hepatocyte glucose produc-
tion and hydrophobicity of the drugs.(a) IC50s
were determined for each drug on G6Pase promoter
activity using LLHG cells. Calculated hydrophobicity
for each compound was also determined. The re-
lationship between log IC50 and clogD is presented.
Plot of (left to right) biguanide, metformin and
phenformin (triangles) and (left to right) DG4, DG5,
DG6, DG7, DG8 and DG10 (squares). A lower log
IC50 indicates a more potent compound, these values
are tabulated in Table 2. Hydrophobicity plots of
selected structures are provided in supplementary
Figs. 3 and 4. (b) Comparison of 1 μM DG8 and 1 mM
DG8N on G6Pase promoter activity. Dex/cAMP was
used to stimulate the promoter. Ins denotes insulin.
In (a) and (b) eﬀects of each dose were measured at
least six times, each from a separate well of cells. (c)
Primary hepatocytes were treated in the presence or
absence of DG5, DG8 and DG8N with and without
100 µM cAMP and glucose production measured as
described in the Methods. A one-way ANOVA was
carried out. (d) Primary hepatocytes were serum
starved overnight and then were treated with the
diguanides shown for 3 h, prior to 15 min treatment
with TNFα before lysis and SDS-PAGE as detailed in
the Methods. Immunoblotting was performed using
antibodies described in Fig. 1. In addition, data is
shown from an antibody for IKKα and one for IκB.
The phosphorylation and protein degradation re-
sponses for IκB are representative of observations
from at least three similar experiments. Quantitation
of these replicates by densitometry appears in
Supplementary Fig. 5.
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TNFα-induced IκB degradation (Fig. 3d and Supplementary Fig. 5a-c).
3.3. A minimum hydrocarbon chain length aﬀects potency of diguanides on
AMPK, gluconeogenic gene expression and hepatocyte glucose output
Next, we examined the eﬀect of branching of the hydrocarbon chain
connecting the guanides in the DG molecule. We synthesized three
further molecules, depicted in Fig. 4a. 2-methyl DG6 is a branched
isomer of DG6. In this molecule the length of the hydrocarbon linker
remains the same as the threshold compound DG5. In addition, two
branched isomers of DG5 were generated with shorter hydrocarbon
linkers. LCMS data in Fig. 4b indicated each compound was> 95%
pure, with the exception of the 2,2-dimethyl isomer with estimated
purity of 90%. MS and MS2 data is presented in Supplementary
Fig. 6a,b. When we compared these analogues side by side, we found
that only the 2-methyl DG6 isomer induced AMPK signalling and sup-
pressed S6 phosphorylation (Fig. 4c, Table 1b) and hepatocyte glucose
production (Fig. 4d), indicating that in addition to possible contribu-
tions of hydrophobicity in itself, the DG compounds’ low micromolar
signalling eﬀects depend on a minimum hydrocarbon chain length of 5
carbons.
3.4. Mitochondrial responses to phenformin and diguanides diﬀer from
metformin
One possible explanation for the overlap in potencies that we ob-
served between phenformin and diguanides is that there are targets for
hydrophobic guanide-containing compounds that are inhibited by
phenformin and with progressively increasing potency by diguanides.
To study this further we investigated whether other cellular eﬀects of
phenformin correlate more closely with diguanides than metformin.
Consistent with this we found that phenformin and diguanides inhibited
mitochondrial dehydrogenase activity in cells, with IC50s in the WST-1
assay corresponding very closely with IC50s on the G6Pase promoter
(Table 2, Fig. 5. DGs left to right are DG4, DG5, DG6, DG7, DG8 and
DG10. Phenformin is the only triangle), whilst in contrast, we were
unable to establish IC50s in the WST-1 assay for metformin and bi-
guanide, despite them eﬃciently inhibiting G6Pase (Fig. 3a). In Sea-
horse microplate studies to measure mitochondrial respiratory activity
in cells, we found that DG5, DG10, metformin and phenformin each
suppressed oxygen consumption to a similar degree (Fig. 6a,b). In other
experimental approaches however, further marked diﬀerences were
detected between metformin and the other drugs. In a conventional
oxygen electrode chamber, direct measurement of eﬀects on oxidation
of the NADH/NAD+ couple by liver submitochondrial particles corre-
sponded much more closely with eﬀects on the WST-1 assay. Eﬀects of
both phenformin and DG5 on NADH oxidation were observed at much
lower concentrations than responses to metformin (Fig. 7). The eﬀects
of metformin and DG8 on intact mitochondria were also diﬀerent.
Treatment of mitochondria with DG8 modestly reduced oxygen con-
sumption and reduced the NADH/NAD+ couple, consistent with com-
plex I inhibition (Fig. 8). Once oxygen was depleted however, the
NADH/NAD+ couple did not respond, indicative of mitochondrial de-
terioration. Metformin treatment also modestly reduced oxygen
Fig. 4. Cell eﬀects of branched diguanide isomers.(a) Structures of diguanide isomers. (b) LCMS of synthesized compounds. Grey arrow denotes guanidylated impurities carried over
from starting material. (c) H4IIE liver cells had serum removed for 2 h and then were treated with the compounds shown for 3 h, prior to lysis, SDS-PAGE and immunoblotting as detailed
in the Methods and Fig. 1. Densitometric determination of IC50s and EC50s of these replicates is also given in Table 1a, c, n=3. (d) Primary hepatocytes were treated in the presence or
absence of 2 mM metformin (Met), 50 µM DG5, 100 µM 2-methyl DG6 isomer, 100 µM 1-ethyl DG5 isomer or 100 µM 2,2 dimethyl DG5 isomer and glucose production measured as
described in the Methods. Each bar of a graph consists of data from at least three separate measurements, each from a separate dish of cells. A one-way ANOVA was carried out.
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consumption but in contrast to DG8, this was accompanied by acute
oxidation of the NADH/NAD+ couple (Fig. 8) and in addition, once
oxygen was depleted, the NADH/NAD+ couple responded to this, in-
dicating that the mitochondria remained functional (Fig. 8).
In a ﬁnal series of experiments, we compared metformin and DG5
on complex I electron transfer activity to artiﬁcial electron acceptors
K3Fe(CN)6 and paraquat, as previous studies have shown that met-
formin has opposing eﬀects on these, inhibiting NADH:paraquat elec-
tron transfer reactions, whilst stimulating NADH:ferricyanide electron
transfer [30]. With metformin we observed similar eﬀects to those
published previously. The direction of the responses to DG5 was the
same; however, there were important diﬀerences between the two
drugs. The eﬀects of metformin and DG5 on K3Fe(CN)6 had similar
shaped dose-response curves, with>50% maximal activity achieved at
12.5 mM for both drugs (Fig. 9a). In contrast, particularly at low con-
centrations of drug, the dose-eﬀect response of metformin on paraquat
was much shallower than that observed with DG5 (Fig. 9b). Conse-
quently the IC50 of metformin on electron donation to paraquat was
almost an order of magnitude less potent than DG5 (metformin IC50
91 mM (95% CI 69–118); DG5 IC50 12 mM (95%CI 9–15)).
4. Discussion
4.1. Similarities and diﬀerences between cellular responses to biguanides
and diguanides
In this study, we synthesized a series of diguanide compounds, to
compare their action on cells with biguanides. Diguanides are met-
formin analogues where two guanide groups are separated by an alkyl
chain of variable length. Extension of this chain from 4 to 10 carbons
yields compounds with increasing hydrophobicity, and anti-hypergly-
caemic eﬃcacy. We investigated whether these compounds produced
metformin-like eﬀects on cell signalling, including elevation of AMPK
phosphorylation and dephosphorylation of S6. We found that DG4 had
little or no eﬀect but DG5-DG10 had eﬀects reminiscent of metformin
and both DG5 and DG8 suppressed hepatocyte glucose production.
Consistent with earlier in vivo data that these more hydrophobic di-
guanides are much more potent than metformin [11], we found that
their eﬀects occurred in the very low micromolar range, in striking
contrast to metformin, where millimolar amounts of the drug are re-
quired for acute eﬀects on signalling. In addition to the relationship
between hydrophobicity and DG potency in unbranched diguanides, we
found that branching of DGs, if it generated a hydrocarbon chain
shorter than ﬁve carbons, resulted in compounds without activity on
glucose production. These data indicate that the structure of the hy-
drocarbon chain also contributes to molecular recognition/access as-
pects of drug action, reminiscent of recent work on biguanide analogues
[47].
The diﬀerences between biguanides and diguanides are consistent
with the notion that metformin and diguanides employ diﬀerent me-
chanisms once they access the mitochondria. The diﬀerence is unlikely
to be due to the increased charge of diguanides, as monoalkylguanides,
which possess a single charge like metformin, are even more potent
inhibitors of mitochondria than diguanides [13]. We also measured the
eﬀects of biguanides and diguanides on gluconeogenic gene expression.
At the longer time-point of these measurements, even DG4 reduced
gluconeogenic gene expression much more potently than metformin.
Phenformin was the most potent of the biguanides, within the range
exhibited by diguanides, suggesting that phenformin but not metformin
might be suﬃciently hydrophobic to share a target with the diguanides.
Fig. 5. Relationship between inhibition of dehydrogenase activity in cells (IC50)
and hydrophobicity of the drugs. IC50s on cellular dehydrogenase activity were de-
termined for each drug using WST-1, tabulated in Table 2. Calculated hydrophobicity for
each compound was used as for Fig. 3a to depict the relationship between log IC50 and
clogD. Plot of phenformin (triangle) and (left to right) DG4, DG5, DG6, DG7, DG8 and
DG10 (squares). A lower log IC50 indicates a more potent compound. Eﬀects of each
dose were measured at least six times, each from a separate well of cells.
Fig. 6. Mitochondrial responses to biguanides and
diguanides. H4IIE cells were treated with the drugs
shown (2 mM metformin, 250 μM phenformin, 100 μM
DG5 and 10 μM DG10) and oxygen consumption mea-
sured in a Seahorse metabolic ﬂux analyzer. Baseline
OCR was measured for 30 mins before injection of ap-
propriate compounds. OCR was continuously measured
for a period of 145 min (a) before uncoupling by addi-
tion of 100 μM 2,4 dinitrophenol (2,4, DNP) for 10 min
(b). A one-way ANOVA was carried out. Each data point
consist of measurements from at least eight separate
wells of cells.
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4.2. Comparison of eﬀects of biguanides and diguanides on mitochondrial
responses
Using Seahorse microplate methodology, we found that biguanides
and diguanides suppressed oxygen consumption rate (OCR) to a similar
extent (Fig. 6) and with either drug type, the OCR following uncoupling
with DNP was suppressed, consistent with previous data for metformin
[2,48] suggesting disruption of the electron transport chain. Diﬀerences
between metformin and the other drugs were apparent however when
we carried out more detailed investigations. First, we considered eﬀects
of the drugs on the NADH/NAD+ couple in SMPs and intact
mitochondria, where the drugs are thought to accumulate. Previous
results showed for example that biguanides inhibit NADH oxidation in
SMPs at concentrations much higher than those required to induce re-
spiratory inhibition in cells [14,30]. The discrepancy in doses required
is understood to owe at least in part to protracted accumulation of these
drugs into the mitochondria, such that short term in vitro studies ne-
cessitate higher doses [30]. Expanded to include diguanides, we found
that both phenformin and DG5 but not metformin inhibited NADH
oxidation, suggesting that inhibition of complex I corresponds well with
eﬀects of these drugs that we measured on mitochondrial dehy-
drogenase activity in cells. One possible reason for the diﬀerences be-
tween metformin and other drugs could be that responses to this drug
are self-limiting, because metformin is understood to require active
mitochondria in order to accumulate [14]; however in SMPs, the drugs
have free access to the enzymes but even here metformin remains much
less potent than phenformin and even a diguanide whose calculated
hydrophobicity is less than metformin. The eﬀects of phenformin and
DG5 were also qualitatively diﬀerent, with the inhibition by DG5 being
instantaneous, whilst phenformin's eﬀects took longer to develop and
appeared similar to eﬀects observed with 100 mM metformin added to
SMPs, which were previously attributed to biguanides stabilizing
Fig. 7. Eﬀects of biguanides and diguanides on NADH oxidation in sub-
mitochondrial particles from rat liver. Representative responses to metformin n=5
(a), phenformin n=4 (b) and DG5 n=3 (c) on NADH oxidation in SMPs. Incubation
conditions: 137 mM KCl, 19.5 mM HEPES, 5.6 mM potassium phosphate, 2.9 mM MgCl2,
1 mM EDTA, pH 7.2. 0.23 mg protein, total volume 0.615 ml.
Fig. 8. Eﬀects of metformin and DG8 on NADH ﬂuorescence in isolated rat liver
mitochondria. Incubation conditions 130 mM KCl, 2.9 mM mannitol, 3 mM sucrose,
19 mM HEPES, 4.6 mM potassium phosphate, 2.8 mM MgCl2, 0.9 mM EDTA, 0.04 mM
EGTA, 0.02% fatty acid-free bovine serum albumin. 1.7 mg protein, total volume 2.6 ml,
pH 7.2. Representative responses are presented, each drug was tested at least three times.
(a) Eﬀect of metformin on NADH ﬂuorescence and oxygen consumption. Final con-
centrations after addition as marked in the graph: 2.7 mM malonate 5.3 mM glutamate,
2.7 mM malate, 1 mM ADP, metformin 1.9 mM, metformin 10.9 mM. (b) Eﬀect of DG8 on
NADH ﬂuorescence and oxygen consumption. Final concentrations after additions:
2.7 mM malonate 5.3 mM glutamate, 2.7 mM malate, 1 mM ADP. Aqueous saturated
solution of DG8 was added three times as indicated.
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‘deactive’ forms of complex I [30,49] that arise in the absence of NADH.
This suggests that DGs may target active conformations of complex I,
whereas biguanides selectively target the ‘deactive’ conformation, al-
though mitochondrial swelling, which we have found is induced by
phenformin (data not shown), provides an alternative explanation for
the unusually slow development of eﬀects on oxygen consumption we
observed with this drug
Qualitative and quantitative diﬀerences were also observed in intact
mitochondria. Despite a substantial reduction of the NADH/NAD+
couple by DG8 addition, oxygen consumption was only modestly in-
hibited. NADH is the only electron donor in this setting and so these
results are diﬃcult to interpret. Once oxygen was depleted, the NADH/
NAD+ couple did not respond to this either. Taken together with the
data in SMPs, this suggests that hydrophobic guanide-containing com-
pounds but not metformin may to varying degrees trigger mitochon-
drial swelling and mitochondrial pore permeability transition. Similar
slow inhibition of oxygen consumption of intact mitochondria by DG10
was described previously [13]. Metformin also reduced oxygen con-
sumption but in striking contrast to DG8, the mitochondria did not
deteriorate with metformin and the drug acutely oxidised the NADH/
NAD+ couple (Fig. 8). Reduction of NADH/NAD+ following oxygen
depletion suggests that substrate transport, which is mediated mainly
by malate aspartate shuttle components in isolated mitochondria, is still
functional even in the presence of high concentrations of metformin.
In recent in vitro studies it was shown that besides inhibiting NADH:
hexaammineruthenium(III) and NADH:paraquat electron transfer re-
actions, metformin-dependent loosening of nucleotide binding from the
reduced ﬂavin stimulates NADH:ferricyanide and shunting of electrons
from NADH directly to O2 with production of reactive oxygen species
including superoxide [30,50]. In addition to the diﬀerences we ob-
served in intact mitochondria, we found that at modest doses, DG5 was
a much more potent inhibitor than metformin of NADH:paraquat
electron transfer, while both drugs exhibited a similar dose response
curve of stimulation for NADH:ferricyanide electron transfer. The
physiological signiﬁcance of the diﬀerences in electron transfer to these
hydrophilic electron acceptors is uncertain. Oxidation of NADH/NAD+
by metformin in intact mitochondria might suggest that stimulation of
complex I electron transfer to generate reactive oxygen species is more
signiﬁcant for this drug, with complex I inhibition the more important
eﬀect for diguanides, with phenformin potentially exploiting both me-
chanisms. This suggests metformin but not diguanides may selectively
divert NADH electron transfer to non-energy-transducing reactions,
which could in principle explain some of the suppression of weight gain
associated with use of the drug. Recent mutational analysis of bacterial
complex I conﬁrms that NADH oxidation and proton transfer coupling
ratios are modiﬁable [51]. Control experiments suggest that the
concentrations of metformin used do not cause mitochondrial swelling
(data not shown) and in addition, similar diﬀerences on the NADH/
NAD+ couple were obtained previously comparing phenformin with
octylguanidine [52]. Taken together, these results suggest metformin,
phenformin and diguanides each modulate mitochondrial oxidation of
complex I substrates by distinct mechanisms.
5. Conclusion
A variety of guanide-containing drugs inhibit the mitochondria. We
found that even a single guanide group attached to a lipophilic tail is a
viable pharmacophore for these eﬀects. We present additional evidence
however that metformin does not produce the mitochondrial damage
observed with more hydrophobic guanide-containing drugs, inhibiting
the mitochondria by a distinctive mechanism resulting in oxidation of
the NADH/NAD+ couple. Our results strongly suggest that metformin,
but none of the other guanide-containing drugs tested, inhibits energy
transduction by selectively suppressing eﬃcient coupling of the redox
and proton transfer domains of complex I. Further study of these dif-
ferences might account for the clinical observations that hydrophobic
alkylguanides and diguanides are toxic [12], hydrophobic biguanides
such as buformin and phenformin are readily capable of inducing lactic
acidosis [53], whilst metformin does not very readily exhibit either of
these properties [54] but does suppress weight gain [29].
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Fig. 9. Eﬀect of metformin and DG5 on electron
donation from complex I to hydrophilic electron
acceptors.(a,b) The eﬀect of dose responses of
metformin and DG5 on reduction of K3Fe(CN)6 (a)
and paraquat (b). A two-way ANOVA was carried out
to determine diﬀerences between drug treatments.
Each data point is composed of measurements of at
least six individual wells.
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